NASDAQ$ORGO
Organogenesis Holdings Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported a strong third quarter with significant revenue growth and improved profitability.
Organogenesis Holdings Inc. reported a 57% increase in net revenue for Q3 2020, reaching $100.8 million compared to $64.3 million in Q3 2019. The company also saw a net income of $20.9 million, a significant turnaround from the net loss of $10.7 million in the same quarter of the previous year. The growth was driven by strong performance in both Advanced Wound Care and Surgical & Sports Medicine product categories.
- Net revenue increased by 57% year-over-year, exceeding expectations.
- Net income improved significantly, reaching $20.9 million compared to a net loss in the previous year.
- Advanced Wound Care products saw a 66% increase in revenue, while Surgical & Sports Medicine products increased by 9%.
- The acquisition of CPN Biosciences is expected to enhance growth in the office channel.
Headline financials
Revenue & EPS history
Organogenesis · Revenue · Quarterly
$101M
Revenue by segment
Organogenesis · $101M total across 2 segments · Q3 2020
- Advanced Wound Care$90M+65.7%89.3%
- Surgical & Sports Medicine$10.8M+8.6%10.7%
Forward guidance
The company reaffirmed its financial guidance for the full year 2020, expecting net revenue between $311 million and $314 million.
Tailwinds
- Net revenue is expected to grow by approximately 19% to 20% year-over-year.
- Advanced Wound Care products are projected to grow by approximately 24% to 25% year-over-year.
- Company anticipates reporting positive GAAP net income for the three months ending December 31, 2020.
- Company expects to report positive Adjusted EBITDA for the three months ending December 31, 2020.
- Company expects to report positive GAAP net income and positive Adjusted EBITDA for the full fiscal year 2020 period.
Headwinds
- Surgical & Sports Medicine products are expected to decrease by approximately 3% to 6% year-over-year.
- Net revenue from PuraPly products is expected to decrease by approximately 5% to 6% year-over-year.
- The company has incurred significant losses since inception and anticipates that it will incur substantial losses for the foreseeable future
- The company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition.
- Rapid technological change could cause the company’s products to become obsolete and if the company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+2.8%
Avg return
Earnings day
+3.2%
Avg return
5 days after
+0.5%
Avg return
30 days after
47%
17 / 36 earnings
Positive
+102.3%
Q4 2024
Best reaction
-42.4%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | -6.2% | -5.9% | |
| Q4 2025 | -13.8% | -22.4% | -38.1% | |
| Q3 2025 | +44.1% | +66.6% | +21.9% | |
| Q1 2025 | -42.4% | -43.6% | -43.3% | |
| Q4 2024 | +102.3% | +95.8% | +46.6% | |
| Q3 2024 | +26.6% | +10.3% | +0.9% | |
| Q2 2024 | +2.0% | +6.4% | -1.2% | |
| Q1 2024 | +31.2% | +23.2% | +19.0% | |
| Q4 2023 | -16.3% | -20.3% | -18.6% | |
| Q3 2023 | +6.8% | +22.9% | +62.4% | |
| Q2 2023 | -25.7% | -27.0% | -31.6% | |
| Q1 2023 | +29.7% | +43.2% | +81.1% | |
| Q4 2022 | +11.0% | -2.9% | -13.1% | |
| Q3 2022 | -18.3% | -11.5% | -17.7% | |
| Q2 2022 | -25.2% | -26.6% | -44.0% | |
| Q1 2022 | +4.6% | +9.8% | -9.3% | |
| Q4 2021 | +18.1% | +15.6% | +2.4% | |
| Q3 2021 | -6.4% | -5.0% | -16.1% | |
| Q2 2021 | +1.9% | +2.5% | +8.2% | |
| Q1 2021 | -15.3% | -11.3% | -28.7% | |
| Q4 2020 | +3.8% | +8.5% | +31.4% | |
| Q3 2020 | +8.2% | +5.2% | +20.2% | |
| Q2 2020 | +0.7% | +1.5% | +3.2% | |
| Q1 2020 | -9.9% | -18.8% | +4.2% | |
| Q4 2019 | -16.2% | +11.6% | +23.5% | |
| Q3 2019 | +10.3% | +8.8% | -36.1% | |
| Q2 2019 | -4.7% | -10.8% | +26.5% | |
| Q1 2019 | -0.4% | +1.0% | +0.7% | |
| Q4 2018 | -3.0% | -5.3% | -16.8% | |
| Q4 2017 | -3.0% | -5.3% | -16.8% | |
| Q2 2018 | +0.3% | +0.2% | +0.1% | |
| Q1 2018 | +0.0% | +0.4% | +0.3% | |
| Q3 2017 | +0.1% | +0.1% | -1.0% | |
| Q2 2017 | +0.0% | +0.1% | +1.5% | |
| Q1 2017 | -0.3% | -0.3% | +0.5% | |
| Q4 2016 | +0.0% | +0.0% | +0.0% | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro